CEL-SCI Corporation (CVM)

US — Healthcare Sector
Peers: INMB  BRNS  MRSN  ALGS  KZR  OKUR  TPST  XFOR  FGEN  PDSB 

Automate Your Wheel Strategy on CVM

With Tiblio's Option Bot, you can configure your own wheel strategy including CVM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CVM
  • Rev/Share 0.0
  • Book/Share 1990.7286
  • PB 2.7528
  • Debt/Equity 588.0713
  • CurrentRatio 2.2602
  • ROIC -0.0011

 

  • MktCap 37656297.0
  • FreeCF/Share -2.1406
  • PFCF -2.1946
  • PE -1.7286
  • Debt/Assets 0.3333
  • DivYield 0
  • ROE -2.4036

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

CEL-SCI Reports Fiscal 2025 Results
CVM
Published: December 29, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

Read More
image for news CEL-SCI Reports Fiscal 2025 Results
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CVM
Published: August 13, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.

Read More
image for news CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
CVM
Published: July 11, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.

Read More
image for news CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Announces Pricing of Public Offering
CVM
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of public offering.

Read More
image for news CEL-SCI Announces Pricing of Public Offering
CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CVM
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI'S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.

Read More
image for news CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CEL-SCI Announces Combination of Common Stock
CVM
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces combination of common stock.

Read More
image for news CEL-SCI Announces Combination of Common Stock
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
CVM
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.

Read More
image for news CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

About CEL-SCI Corporation (CVM)

  • IPO Date 1983-12-08
  • Website https://cel-sci.com
  • Industry Biotechnology
  • CEO Geert R. Kersten
  • Employees 43
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.